Med-Mastodon

0 posts0 participants0 posts today

Giuseppe Michieli<a href="https://mstdn.science/tags/Clinical" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Clinical</a> <a href="https://mstdn.science/tags/profile" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#profile</a> analysis of <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/community" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#community</a> <a href="https://mstdn.science/tags/infections" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#infections</a> during periods with <a href="https://mstdn.science/tags/omicron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#omicron</a> <a href="https://mstdn.science/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a>, <a href="https://mstdn.science/tags/BA4" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA4</a>/5, and <a href="https://mstdn.science/tags/XBB" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#XBB</a> dominance in <a href="https://mstdn.science/tags/HK" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#HK</a>: a prospective cohort studySource: Lancet Infectious Diseases, SummaryBackgroundExisting studies on SARS-CoV-2 infection have mainly focused on severe clinical outcomes; understanding of the clinical severity profile of general community infections is poor. We aimed to assess and compare the clinical profiles of infections with…<a href="https://etidioh.wordpress.com/2024/10/15/clinical-profile-analysis-of-sars-cov-2-community-infections-during-periods-with-omicron-ba2-ba4-5-and-xbb-dominance-in-hk-a-prospective-cohort-study/" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://etidioh.wordpress.com/2024/10/15/clinical-profile-analysis-of-sars-cov-2-community-infections-during-periods-with-omicron-ba2-ba4-5-and-xbb-dominance-in-hk-a-prospective-cohort-study/</a>

Edelruth In The Wrong TimelineI am so frustrated right now. I am trying to find out whether the at-home covid rapid tests can detect the new BA.2 strain(s). I'm finding lots of "it should work because of its design".That's nice.Has there been any lab testing of the rapid tests on this/these new strains? Or, are we going to just wander along on "should"?<a href="https://mastodon.online/tags/Covid" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Covid</a> <a href="https://mastodon.online/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a> <a href="https://mastodon.online/tags/RapidTesting" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#RapidTesting</a>

Dorothea Zwölfer (sie)Wirksamkeit der Boosterimpfung gegen <a href="https://federation.network/tags/Corona" rel="nofollow noopener noreferrer" target="_blank">#Corona</a> nun nachgewiesen: >>Eine Studie der Klinik für Rheumatologie und Immunologie der Medizinischen Hochschule Hannover (MHH) schließt nun diese Lücke. In Kooperation mit dem MHH-Institut für Immunologie und dem Deutschen Primatenzentrum Göttingen haben die Forschenden die weltweit erste Publikation über den neuen <a href="https://federation.network/tags/XBB" rel="nofollow noopener noreferrer" target="_blank">#XBB</a>.1.5 basierten Impfstoff von Biontech veröffentlicht. Im Rahmen der „<a href="https://federation.network/tags/COVID-19" rel="nofollow noopener noreferrer" target="_blank">#COVID-19</a> Contact (CoCo)“-Studie der MHH wurden 53 MHH-Beschäftigte untersucht, die den <a href="https://federation.network/tags/Impfstoff" rel="nofollow noopener noreferrer" target="_blank">#Impfstoff</a> erhalten haben. Anschließend wurde deren Immunreaktion gemessen. Das Ergebnis: Nach der <a href="https://federation.network/tags/Impfung" rel="nofollow noopener noreferrer" target="_blank">#Impfung</a> mit dem neuen <a href="https://federation.network/tags/Booster" rel="nofollow noopener noreferrer" target="_blank">#Booster</a> waren die Antikörper gegen <a href="https://federation.network/tags/Omikron" rel="nofollow noopener noreferrer" target="_blank">#Omikron</a> <a href="https://federation.network/tags/Varianten" rel="nofollow noopener noreferrer" target="_blank">#Varianten</a> deutlich angestiegen. Die Arbeit ist in der renommierten Fachzeitschrift „The Lancet Infection Diseases“ veröffentlicht worden. [.. ] „Wir haben nicht nur eine große Menge neutralisierender Antikörper gegen Omikron XBB.1.5 gefunden, sondern auch gegen andere <a href="https://federation.network/tags/Unter-Varianten“" rel="nofollow noopener noreferrer" target="_blank">#Unter-Varianten“</a>, sagt die Oberärztin Professorin Dr. Alexandra Dopfer-Jablonka, die gemeinsam mit ihrem Klinikkollegen Professor Dr. Georg Behrens die Immunstudie leitet. Das bedeutet, der Impfstoff ruft die Immunabwehr nicht nur gegen die aktuell dominierende Corona-Variante XBB.1.5 auf den Plan, sondern aktiviert die körpereigene Abwehr auch gegen die sich gerade ausbreitende Varianten „<a href="https://federation.network/tags/Pirola“" rel="nofollow noopener noreferrer" target="_blank">#Pirola“</a> (<a href="https://federation.network/tags/BA2" rel="nofollow noopener noreferrer" target="_blank">#BA2</a>.86) und „<a href="https://federation.network/tags/Eris“" rel="nofollow noopener noreferrer" target="_blank">#Eris“</a> (<a href="https://federation.network/tags/EG1" rel="nofollow noopener noreferrer" target="_blank">#EG1</a>.5). „Die <a href="https://federation.network/tags/B-Zellen" rel="nofollow noopener noreferrer" target="_blank">#B-Zellen</a>, die Antikörper gegen Omikron produzieren, wurden signifikant mehr und auch die <a href="https://federation.network/tags/T-Zellen" rel="nofollow noopener noreferrer" target="_blank">#T-Zellen</a> wurden durch die Impfung gestärkt“, erklärt die Rheumatologin. „Die Daten zeigen, dass die neue <a href="https://federation.network/tags/Booster-Impfung" rel="nofollow noopener noreferrer" target="_blank">#Booster-Impfung</a> ihr Ziel erreicht und darüber hinaus auch Antikörper gegen neue <a href="https://federation.network/tags/SARS-CoV-2" rel="nofollow noopener noreferrer" target="_blank">#SARS-CoV-2</a> Varianten induziert.“ [..] Eine <a href="https://federation.network/tags/Auffrischungsimpfung" rel="nofollow noopener noreferrer" target="_blank">#Auffrischungsimpfung</a> mit dem neuen, angepassten Impfstoff ist laut Ständiger Impfkommission (<a href="https://federation.network/tags/Stiko" rel="nofollow noopener noreferrer" target="_blank">#Stiko</a>) für alle empfehlenswert, die 60 Jahre oder älter sind. Zudem sollten sich alle Menschen boostern lassen, die wegen einer <a href="https://federation.network/tags/Grunderkrankung" rel="nofollow noopener noreferrer" target="_blank">#Grunderkrankung</a> ein besonderes Risiko für einen schweren Krankheitsverlauf haben. Außerdem empfiehlt die Stiko die Auffrischungsimpfung für Bewohnerinnen und Bewohner von <a href="https://federation.network/tags/Pflegeheimen" rel="nofollow noopener noreferrer" target="_blank">#Pflegeheimen</a> sowie für# Beschäftigte im Pflege- und Gesundheitsbereich. Die Auffrischungsimpfung sollte jährlich wiederholt werden, vorzugsweise im Herbst. << <a href="https://idw-online.de/de/news826159" rel="nofollow noopener noreferrer" target="_blank">https://idw-online.de/de/news826159</a>

Benjamin Carr, Ph.D. 👨🏻‍💻🧬Global <a href="https://hachyderm.io/tags/COVID" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#COVID</a> monitoring is crashing as BA.2.86 <a href="https://hachyderm.io/tags/COVIDvariant" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#COVIDvariant</a> raises alarm The number of mutations in <a href="https://hachyderm.io/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a>.86's critical <a href="https://hachyderm.io/tags/spikeprotein" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#spikeprotein</a> is over 30, rivaling the number seen in the original omicron subvariant, <a href="https://hachyderm.io/tags/BA1" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA1</a>, which went on to cause a tidal wave of cases and hospitalizations. The spike mutations appear geared toward evading neutralizing <a href="https://hachyderm.io/tags/antibody" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#antibody</a> protections built up from past infections and <a href="https://hachyderm.io/tags/vaccinations" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#vaccinations</a>. "This is on the shoulders of governments right now." <a href="https://arstechnica.com/health/2023/08/global-covid-monitoring-is-crashing-as-ba-2-86-variant-raises-alarm/" rel="nofollow noopener noreferrer" target="_blank">https://arstechnica.com/health/2023/08/global-covid-monitoring-is-crashing-as-ba-2-86-variant-raises-alarm/</a>

Giuseppe MichieliAssociations of <a href="https://mstdn.science/tags/COVID19" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#COVID19</a> <a href="https://mstdn.science/tags/symptoms" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#symptoms</a> with <a href="https://mstdn.science/tags/omicron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#omicron</a> subvariants <a href="https://mstdn.science/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a> and <a href="https://mstdn.science/tags/BA5" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA5</a>, host status, and <a href="https://mstdn.science/tags/clinical" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#clinical</a> outcomes in <a href="https://mstdn.science/tags/Japan" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Japan</a>: a registry-based observational study - Lancet ID.: <a href="https://doi.org/10.1016/S1473-3099(23)00271-2" rel="nofollow noopener noreferrer" target="_blank">https://doi.org/10.1016/S1473-3099(23)00271-2</a> <a href="https://mstdn.science/tags/epidemic" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#epidemic</a> <a href="https://mstdn.science/tags/pandemic" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#pandemic</a> <a href="https://mstdn.science/tags/epidemiology" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#epidemiology</a>

Giuseppe MichieliIntrinsic and effective <a href="https://mstdn.science/tags/severity" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#severity</a> of <a href="https://mstdn.science/tags/COVID19" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#COVID19</a> cases infected with the ancestral strain and <a href="https://mstdn.science/tags/Omicron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Omicron</a> <a href="https://mstdn.science/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a> <a href="https://mstdn.science/tags/variant" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#variant</a> in <a href="https://mstdn.science/tags/HK" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#HK</a> <a href="https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad236/7208626?rss=1" rel="nofollow noopener noreferrer" target="_blank">https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad236/7208626?rss=1</a> <a href="https://mstdn.science/tags/epidemiology" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#epidemiology</a> <a href="https://mstdn.science/tags/cfr" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#cfr</a> <a href="https://mstdn.science/tags/resources" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#resources</a> <a href="https://mstdn.science/tags/hospital" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#hospital</a> <a href="https://mstdn.science/tags/wuhan" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#wuhan</a> <a href="https://mstdn.science/tags/china" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#china</a>

Giuseppe MichieliLong term anti- <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/antibody" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#antibody</a> <a href="https://mstdn.science/tags/kinetics" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#kinetics</a> and correlate of <a href="https://mstdn.science/tags/protection" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#protection</a> against <a href="https://mstdn.science/tags/Omicron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Omicron</a> BA.1/ <a href="https://mstdn.science/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a> infection <a href="https://www.nature.com/articles/s41467-023-38744-7" rel="nofollow noopener noreferrer" target="_blank">https://www.nature.com/articles/s41467-023-38744-7</a>

Giuseppe MichieliReal-world <a href="https://mstdn.science/tags/effectiveness" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#effectiveness</a> of primary series and <a href="https://mstdn.science/tags/booster" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#booster</a> doses of inactivated <a href="https://mstdn.science/tags/COVID19" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#COVID19</a> <a href="https://mstdn.science/tags/vaccine" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#vaccine</a> against <a href="https://mstdn.science/tags/Omicron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Omicron</a> <a href="https://mstdn.science/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a> <a href="https://mstdn.science/tags/variant" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#variant</a> infection in <a href="https://mstdn.science/tags/China" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#China</a>: a retrospective cohort study <a href="https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad090/7099684?rss=1" rel="nofollow noopener noreferrer" target="_blank">https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad090/7099684?rss=1</a>

Giuseppe Michieli<a href="https://mstdn.science/tags/Immunity" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Immunity</a> of heterologous and homologous boosted or <a href="https://mstdn.science/tags/convalescent" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#convalescent</a> individuals against <a href="https://mstdn.science/tags/Omicron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Omicron</a> <a href="https://mstdn.science/tags/BA1" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA1</a>, <a href="https://mstdn.science/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a> and <a href="https://mstdn.science/tags/BA4" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA4</a>/5 variants <a href="https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad057/7069351?rss=1" rel="nofollow noopener noreferrer" target="_blank">https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad057/7069351?rss=1</a>

Giuseppe Michieli{<a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/Omicron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Omicron</a>} <a href="https://mstdn.science/tags/BA1" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA1</a>, <a href="https://mstdn.science/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a> and <a href="https://mstdn.science/tags/BA275" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA275</a> variants show comparable <a href="https://mstdn.science/tags/replication" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#replication</a> kinetics, reduced impact on <a href="https://mstdn.science/tags/epithelial" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#epithelial</a> <a href="https://mstdn.science/tags/barrier" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#barrier</a> and elicit cross-neutralizing <a href="https://mstdn.science/tags/antibodies" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#antibodies</a> <a href="https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011196" rel="nofollow noopener noreferrer" target="_blank">https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011196</a>

Giuseppe MichieliComparative <a href="https://mstdn.science/tags/Effectiveness" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Effectiveness</a> of <a href="https://mstdn.science/tags/COVID19" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#COVID19</a> <a href="https://mstdn.science/tags/Vaccines" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Vaccines</a> in Preventing <a href="https://mstdn.science/tags/Infections" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Infections</a> and Disease <a href="https://mstdn.science/tags/Progression" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Progression</a> from <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/Omicron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Omicron</a> <a href="https://mstdn.science/tags/BA5" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA5</a> and <a href="https://mstdn.science/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a>, <a href="https://mstdn.science/tags/Portugal" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Portugal</a> <a href="https://wwwnc.cdc.gov/eid/article/29/3/22-1367_article" rel="nofollow noopener noreferrer" target="_blank">https://wwwnc.cdc.gov/eid/article/29/3/22-1367_article</a>

Giuseppe Michieli<a href="https://mstdn.science/tags/Protection" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Protection</a> conferred by <a href="https://mstdn.science/tags/Delta" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Delta</a> and <a href="https://mstdn.science/tags/BA1" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA1</a> / <a href="https://mstdn.science/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a> <a href="https://mstdn.science/tags/infection" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#infection</a> against <a href="https://mstdn.science/tags/BA4" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA4</a> / <a href="https://mstdn.science/tags/BA5" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA5</a> infection and <a href="https://mstdn.science/tags/hospitalization" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#hospitalization</a>: A Retrospective Cohort Study, The Journal of Infectious Diseases, jiad003, <a href="https://doi.org/10.1093/infdis/jiad003" rel="nofollow noopener noreferrer" target="_blank">https://doi.org/10.1093/infdis/jiad003</a>

Giuseppe Michieli''It is worth noting that <a href="https://mstdn.science/tags/XBB" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#XBB</a> is not a virus mutation, but a <a href="https://mstdn.science/tags/recombinant" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#recombinant</a> strain of two <a href="https://mstdn.science/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a> lineages, <a href="https://mstdn.science/tags/BA2101" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2101</a> and <a href="https://mstdn.science/tags/BA275" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA275</a>. In contrast, the previous major epidemic strains in the United States, BQ.1 and BQ.1.1, both evolved from BA.5.''

Giuseppe MichieliLi, M., Ren, Y., Aw, Z.Q. et al. Broadly neutralizing and protective <a href="https://mstdn.science/tags/nanobodies" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#nanobodies</a> against <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/Omicron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Omicron</a> subvariants <a href="https://mstdn.science/tags/BA1" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA1</a>, <a href="https://mstdn.science/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a>, and <a href="https://mstdn.science/tags/BA4" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA4</a>/5 and diverse <a href="https://mstdn.science/tags/sarbecoviruses" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#sarbecoviruses</a>. Nat Commun 13, 7957 (2022). <a href="https://doi.org/10.1038/s41467-022-35642-2" rel="nofollow noopener noreferrer" target="_blank">https://doi.org/10.1038/s41467-022-35642-2</a>

Giuseppe Michieli<a href="https://mstdn.science/tags/Effectiveness" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Effectiveness</a> of <a href="https://mstdn.science/tags/BNT162b2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BNT162b2</a> and <a href="https://mstdn.science/tags/CoronaVac" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#CoronaVac</a> <a href="https://mstdn.science/tags/COVID19" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#COVID19</a> <a href="https://mstdn.science/tags/vaccination" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#vaccination</a> against asymptomatic and symptomatic <a href="https://mstdn.science/tags/infection" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#infection</a> of <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/omicron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#omicron</a> <a href="https://mstdn.science/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a> in <a href="https://mstdn.science/tags/HK" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#HK</a>: a prospective cohort study, <a href="https://doi.org/10.1016/S1473-3099(22)00732-0" rel="nofollow noopener noreferrer" target="_blank">https://doi.org/10.1016/S1473-3099(22)00732-0</a>

Giuseppe MichieliRössler, A., Netzl, A., Knabl, L. et al. <a href="https://mstdn.science/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a> and <a href="https://mstdn.science/tags/BA5" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA5</a> <a href="https://mstdn.science/tags/omicron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#omicron</a> differ immunologically from both <a href="https://mstdn.science/tags/BA1" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA1</a> omicron and pre-omicron <a href="https://mstdn.science/tags/variants" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#variants</a>. Nat Commun 13, 7701 (2022). <a href="https://doi.org/10.1038/s41467-022-35312-3" rel="nofollow noopener noreferrer" target="_blank">https://doi.org/10.1038/s41467-022-35312-3</a>

Giuseppe MichieliJu, B., Fan, Q., Wang, M. et al. <a href="https://mstdn.science/tags/Antigenic" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Antigenic</a> sin of wild-type <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/vaccine" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#vaccine</a> shapes poor cross- <a href="https://mstdn.science/tags/neutralization" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#neutralization</a> of <a href="https://mstdn.science/tags/BA4" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA4</a>/5/2.75 <a href="https://mstdn.science/tags/subvariants" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#subvariants</a> in <a href="https://mstdn.science/tags/BA2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA2</a> breakthrough infections. Nat Commun 13, 7120 (2022). <a href="https://doi.org/10.1038/s41467-022-34400-8" rel="nofollow noopener noreferrer" target="_blank">https://doi.org/10.1038/s41467-022-34400-8</a>

Recent searches

Search options

Administered by:

Server stats:

#ba2